Cargando…
Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension
Hypertension is a major risk factor for cardiovascular disease that contributes to the premature death of millions of people each year, and identification and treatment of hypertension continues to be a challenge. Guidelines recommend that many patients will require two or more antihypertensive agen...
Autor principal: | Ruilope, Luis M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2663442/ https://www.ncbi.nlm.nih.gov/pubmed/19337537 |
Ejemplares similares
-
Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension
por: Greathouse, Mark
Publicado: (2006) -
Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial
por: Sohn, Il Suk, et al.
Publicado: (2015) -
Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
por: Punzi, Henry A
Publicado: (2011) -
Erratum to: Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial
por: Sohn, Il Suk, et al.
Publicado: (2016) -
Clinical Efficacy and Safety of Combination Therapy with Amlodipine and Olmesartan or an Olmesartan/Hydrochlorothiazide Compound for Hypertension: A Prospective, Open-Label, and Multicenter Clinical Trial in China
por: Gao, Pingjin, et al.
Publicado: (2015)